• Rakovina Therapeutics agreed to settle $235,908.60 in outstanding obligations through common shares at $0.175 per share.
• The settlement covers $125,493.70 in accrued interest on existing 12% unsecured convertible debentures.
• Another $110,414.90 represents outstanding amounts payable to service providers.
• Share issuance remains subject to regulatory approvals, including TSX Venture Exchange approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871745) on November 05, 2026, and is solely responsible for the information contained therein.